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Abstract
Background Patients who are diagnosed with symptom-
atic or ambiguous serous cyst adenoma (SCA) need surgery.
The purpose of this study is to suggest a potential man-
agement plan based on analysis of surgically treated SCAs.
Methods Between August 1995 and December 2010, 38
patients with SCA were surgically treated. Data were
analyzed retrospectively.
Results Among 38 patients, 28 were female and ten were
male. Mean age was 49.6 ± 14.1 years, and five patients
(13.2%) were older than 65 years. Among the five
patients, two were more than 70 years old. Seventeen
patients (44.7%) were symptomatic, and the rest (21, 55.3%)
were incidentally found to have SCA. Twenty-seven patients
underwent open pancreatectomy, and 11 patients received
laparoscopic distal pancreatectomy. Mean tumor size was
4.4 ± 2.8 cm. Most asymptomatic patients of SCA had a
left-sided pancreatic tumor and distal pancreatectomy with
or without splenectomy were frequently performed with
short operative time and less blood transfusion (P \ 0.05).
Minimally invasive surgery was mostly applied to left-
sided tumors less than 5 cm in size (11/19 vs. 0/6,
P = 0.029). Combined resection of the right colon was
performed in two patients (5.3%) due to severe adhesion
associated with large tumors. Significant association was
noted between age and tumor size in asymptomatic patients
(correlation coefficient = 0.541, R2 = 0.293, P = 0.014).
Postoperative pancreatic fistula was observed in five
patients (13.2%, grade B) but could be managed conser-
vatively. No mortality was found.
Conclusion Before SCA causes symptoms or grows lar-
ger than 5 cm, an active surgical approach, such as mini-
mally invasive surgery, needs to be considered.
Keywords Serous cyst adenoma  Surgery 
Minimally invasive surgery  Observation
Neoplastic cysts account for 10–20% of pancreatic cysts,
and malignant cystic neoplasms account for about 1% of
pancreatic malignant tumors [1, 2]. In 1978, Campagno and
Oerterl [3] characterized for the first time 34 pancreatic
serous cyst adenomas (SCAs). The histopathological
characteristics include irregular thick fibrous bands without
specific capsule, nerves, or fairly large blood vessels that
course through or near the cystic tumor. Unlike mucinous
cystic neoplasm or intraductal papillary mucinous neo-
plasm of the pancreas, SCA is generally considered a
benign tumor with almost no malignant potential. There-
fore, only expectant management with serial follow-up is
provided, and surgery is not recommended in the absence
of symptoms. Surgeons may need to wait until clinical
symptoms related to SCA of the pancreas develop. How-
ever, the concept of this traditional approach to SCA of the
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pancreas was based on totally different clinical situations
from those found today.
Recently, asymptomatic benign or borderline malignant
cystic neoplasms of the pancreas are increasingly being
detected on routine medical check-up, resulting from devel-
opment of the socioeconomic conditions of the general pop-
ulation, increasing concern for personal health, and enhanced
quality of axial imaging techniques [4, 5]. In addition,
advances in both surgical techniques of pancreatectomy and
perioperative management have reduced perioperative mor-
bidity and mortality following pancreatectomy to the level
of general acceptance [6]. Furthermore, minimally invasive
(laparoscopic or robotic) pancreatectomy is currently avail-
able and regarded as safe and effective in selected patients
[7, 8]. It is also beneficial in terms of quality of life. Therefore,
it is thought that reconsideration of the rationale for the
traditional approach to SCA of the pancreas is required.
Many clinical elements supporting the rationale for the
traditional expectant management have changed. Taking
these facts into consideration, physicians must reexamine
more appropriate ways of managing SCA of the pancreas.
In this study, we evaluated our institutional experience
with surgically treated pancreatic SCA. Based on our
experience, we suggest a potential strategy for managing
SCA of the pancreas.
Patients and methods
We retrospectively reviewed the medical records of 38
patients who were diagnosed with serous cystadenoma of
the pancreas and who underwent pancreatectomy between
August 1995 and December 2010. In descriptive analysis,
general characteristics of the patients, including age, gen-
der, type of pancreatectomy, and perioperative outcomes,
were evaluated. In comparative analysis, we divided the
patients into two groups according to the presence of
symptoms (symptomatic group and asymptomatic group),
and clinicopathological variables of the two groups were
compared. Categorical variables are expressed as fre-
quency and percentage (%). Continuous variables are
expressed as mean ± standard deviation. v2 and Student
t tests were used where appropriate and linear regression
was applied in correlating patient age to tumor size
according to the presence of symptoms. P values less than
0.05 were regarded as significant.
Results
General characteristics of resected SCAs
Among 38 patients, 28 were female and ten were male;
mean age of all patients was 49.6 ± 14.1 years. Seventeen
patients (44.7%) presented with clinical symptoms,
whereas the rest were incidentally found during routine
medical check-up or evaluation of other, unrelated medical
problems. Abdominal pain and discomfort were the most
frequent symptoms (n = 11, 64.7%), followed by indi-
gestion (n = 6, 35.3%). Seven patients (18.4%) were
associated with previous malignant disease: thyroid cancer
(n = 2), breast cancer (n = 1), cervix cancer (n = 1),
gastric cancer (n = 1), lung cancer (n = 1), and hepatoma
(n = 1). Most tumors (n = 25, 65.8%) were located on the
left side of the pancreas (body and tail), and the rest on the
pancreatic head portion. Tumor enucleation was done in
five patients, conventional pancreatoduodenectomy in 5,
and pylorus-preserving pancreatoduodenectomy in 4, and
distal pancreatectomy with splenectomy in 12, and spleen-
preserving distal pancreatectomy in 12. Since 2005, our
institution has been applying minimally invasive (laparo-
scopic and robotic) pancreatectomy to manage SCA loca-
ted at the distal side of the pancreas. Especially when
considering left-sided SCA, minimally invasive surgery
was mostly applied to tumors less than 5 cm in size (11/19
versus 0/6, P = 0.029) (Table 1). Postoperative compli-
cations were noted in eight patients (21.1%), and all could
be managed conservatively. Postoperative pancreatic fis-
tula was observed in five patients (13.2%, grade B), and
delayed gastric emptying in one patient. Pneumonia with
acute myocardial infarction and wound failure were each
noted in one patient. No mortality was found in this series.
Potential clinical problems derived from SCA
of the pancreas
First, symptoms were clinical problems for patients with
SCA. Surgery was performed on 17 patients (44.7%) who
presented with clinical symptoms. Second, the patients
with SCA larger than 5 cm in size lost the chance to
receive minimally invasive surgery. All six patients
(15.8%) who had tumor larger than 5 cm in size underwent
open distal pancreatectomy (Table 1). Third, older age was
a clinical problem. Five patients (13.2%) were older than
65 years. Among them, two patients were more than
70 years old, and three patients showed clinical symptoms.
Finally, tumor adhesion to adjacent organ was a clinical
Table 1 Procedure pattern according to tumor size for left-sided
SCA (n = 25)
Tumor size P value
\3 cm 3–5 cm C5 cm
Open (n = 14) 3 (60%) 5 (35.7%) 6 (100%) 0.029
MIS* (n = 11) 2 (40.0%) 9 (64.3%) 0
* MIS minimally invasive surgery, including laparoscopic and robotic
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problem in large tumors. In spite of its benign character-
istics, combined resection of the right colon was performed




On comparative analysis between symptomatic and
asymptomatic SCA (Table 2), most asymptomatic patients
of SCA had a left-sided pancreatic tumor, so distal pancre-
atectomy with or without splenectomy was more frequently
performed (P \ 0.05). Therefore, 1.5 h of operation time
could be saved with asymptomatic patients (P \ 0.05), and
transfusion was less frequently given to asymptomatic
patients (P \ 0.05). Other clinical perioperative outcomes
including estimated amount of intraoperative bleeding, and
surgical complications were similar between the groups
(P [ 0.05). Interestingly, no correlation between patient age
and tumor size was observed in the symptomatic patients
(P = 0.597, correlation coefficient = 0.138, R2 = 0.019,
Fig. 1A), while significant association was observed in the
asymptomatic patients (P = 0.014, correlation coeffi-
cient = 0.541, R2 = 0.293, Fig. 1B).
Discussion
In general, when managing SCA of the pancreas, most
surgeons recommend observation with serial follow-up by
means of axial imaging study as long as the tumor is not
directly related to presenting symptoms. Unlike mucinous
cystic tumors and intraductal papillary mucin-producing
tumors of the pancreas, SCAs are considered benign with
almost no malignant potential [9, 10]. However, consid-
ering improvement in socioeconomic conditions, pro-
longed life expectancy, surgical techniques, and
perioperative management, such a passive management
strategy should be reevaluated for the following reasons:
First, the prevalence of cancer in serous cystic neoplasm
(SCN) is known to be about 3%, and a recent literature
review of serous cyst adenocarcinoma [10] reported that
the median age of the patients was 68 years (range
53–85 years) with median tumor size of 11 cm (range
2.5–11 cm). This suggests that even SCNs might eventu-
ally progress to large malignant tumors in the elderly when
not treated appropriately. Second, Tseng et al. [11] recently
estimated the growth rate of SCAs based on serial axial
imaging study. They observed that tumors smaller than
4 cm at presentation grew slowly (only about 0.12 cm/
year), whereas those larger than 4 cm at presentation grew
much faster (1.6 cm/year) and were more likely to develop
symptoms. This suggests that tumor biology may be dif-
ferent according to tumor size, and pancreatic SCNs seem
to aggressively transform as they grow. Our current data
also seem to indirectly support their findings. In the present
study, asymptomatic SCA patients showed significant
correlation between age and tumor size (Fig. 1B), sug-
gesting that asymptomatic SCA, if not treated, may indo-
lently progress to large size in elderly patients. In addition,
applying a minimally invasive approach to large tumors
(more than 5 cm) may be more difficult. In our series, two
patients underwent combined colon resection due to severe
adhesion to large SCA (9.5 and 10 cm, respectively), and
one of them was more than 70 years old. If SCA of the
pancreas is not treated properly in time, clinical problems
such as new symptoms or malignant degeneration may
develop as patients grow older. In such cases, it would be
more difficult to decide a surgical approach because
Table 2 Comparative analysis according to presence of symptoms
Asymptomatic Symptomatic P value
(n = 21) (n = 17)
Age (years) 47.9 ± 12.6 51.7 ± 15.9 0.416
Gender, n (%) 0.726
Female 15 (71.4%) 13 (76.5%)
Male 6 (28.6%) 4 (23.5%)
Tumor size (cm) 3.6 ± 1.9 5.3 ± 3.4 0.091
Tumor location, n (%) 0.005
Proximal 3 (14.3%) 10 (58.8%)
Distal 18 (85.7%) 7 (41.2%)
Surgery 1, n (%) 0.955
Open 15 (71.4%) 12 (70.6%)
MIS* 6 (28.6%) 5 (29.4%)
Surgery 2, n (%) 0.020
Enucleation 3 (14.3%) 2 (11.8%)
PD 0 5 (29.4%)
PPPD 1 (4.8%) 3 (17.6%)
DPS 10 (47.6%) 2 (11.8%)
DP-S 7 (33.3%) 5 (29.4%)
Operation time (min) 203.6 ± 86.8 311.2 ± 135.3 0.009
Bleeding (ml) 339.4 ± 351.7 662.5 ± 780.5 0.153
Transfusion 0.003
No 19 (90.5%) 8 (47.1%)
Yes 2 (9.5%) 9 (52.9%)
LOH (day) 12.2 ± 6.1 18.5 ± 12.9 0.059
Complication, n (%) 0.736
No 17 (81%) 13 (76.5%)
Yes 4 (19%) 4 (23.5%)
* MIS minimally invasive surgery, including laparoscopic and robotic
PD pancreatoduodenectomy, PPPD pylorus-preserving pancreatodu-
odenectomy, DPS distal pancreatectomy with splenectomy, DP-S
distal pancreatectomy without splenectomy, LOH length of hospital
stay
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comorbidity related to patient age and large tumor size
would make clinical situations more complicated. Con-
sidering that SCAs are usually benign, patients and sur-
geons need to avoid such complicated clinical settings.
In the past, it was thought that pancreatectomy should be
avoided as much as possible due to its significant morbidity
and potential mortality following pancreatectomy. How-
ever, operative morbidity and mortality have been reduced
to generally acceptable ranges due to recent advances in
surgical techniques and perioperative management,
including interventional radiology, as well as increased
surgical experience [12, 13]. It is reported that high-volume
centers can now perform pancreatectomy very safely [6–8,
14]. Our study also showed no mortality, and about 20% of
the complications (including 13.2% of grade B postoper-
ative pancreatic fistula) were successfully treated by con-
servative management. This suggests that pancreatectomy
for managing SCA is a safe and reliable procedure. In
addition, minimally invasive (laparoscopic and robotic)
distal pancreatectomy with or without splenectomy is now
regarded as a safe and effective surgical modality in
managing benign and borderline malignant pancreatic
tumors [15, 16]. Even laparoscopic pancreatoduodenec-
tomy is also thought to be safe in expert hands [17]. At our
institute, application of minimally invasive distal pancre-
atectomy to left-sided SCAs has been increasing since
2005. On comparative analysis, left-sided pancreatic tumor
was more frequently found in asymptomatic patients, and
left-sided pancreatectomy was performed without
increased perioperative risk in asymptomatic patients
(Table 2). Minimally invasive approach is increasingly
considered for asymptomatic left-sided SCA. SCN tends to
become a large symptomatic tumor in the end and can
create difficult clinical situations, such as open pancrea-
tectomy, age-related comorbidity, and combined organ
resection in spite of its benign characteristics. Thus, timely
surgical intervention with either conventional open surgery
or minimally invasive surgery is a reasonable strategy in
current clinical practice. Based on the biologic properties
of SCA and our experience, we suggest a potential strategy
for managing SCA of the pancreas (Fig. 2). When a tumor
is directly related to presenting clinical symptoms, pan-
createctomy should be considered regardless of tumor size.
In contrast, it may be better to serially follow an asymp-
tomatic small SCA tumor less than 3 cm. However, in case
of a tumor between 3 and 5 cm, minimally invasive pan-
createctomy needs to be actively considered for well-
selected left-sided SCA as it may grow indolently and then
create difficult clinical problems. Although laparoscopic or
robotic distal pancreatectomy with or without splenectomy
is frequently and safely performed, application of this
procedure should be cautiously considered by an expert at a
high-volume center. If the tumor continues to grow or new
clinical symptoms develop, surgery should be considered
during the serial follow-up with the patient’s full consent
and knowledge of the potential risk of progression and
clinical problems.
Considering patient social activity and the potential
morbidity of pancreatic resection, pancreatectomy for
mostly benign tumors should be avoided. However, when
choosing the traditional approach for asymptomatic SCA,
surgeons may need to take the following factors into con-
sideration: potential risk of pancreatectomy with older age
and practical issues related to long-term follow-up, such as
cost–benefit effectiveness and patient compliance.
Recently, minimally invasive pancreatectomy has been
generally regarded as a safe and effective treatment
A 
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Fig. 1 Correlation between age and tumor size according to
presence of symptoms
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modality for benign and borderline malignant tumors.
According to our results, large symptomatic tumors in need
of surgical intervention are usually found in elderly
patients. These elderly patients might have less chance for
minimally invasive pancreatectomy, and there might be
potential morbidity related to old age, which makes clinical
situations more complicated. Tseng et al. [11] described the
relationship between tumor size and speed of tumor
growth, but no other study has presented data on the rela-
tionship between age and speed of tumor growth. A well-
designed prospective cohort study needs to be conducted
for the evidence-based surgical decision in asymptomatic
SCA of the pancreas.
In summary, SCA of the pancreas is rare but is expected
to be detected more frequently due to easier access to
medical care and improvement in pancreatic imaging
study. According to previous studies and our surgical
experience, the natural course of SCA is thought to be
related to large symptomatic tumors or malignant degen-
eration at older age. Recently, open and minimally invasive
pancreatectomy has been safely performed even in
asymptomatic patients. Timely and appropriate surgical
intervention such as minimally invasive surgery needs to
be actively considered before pancreatic SCA causes
clinical problems.
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